fluoxetine has been researched along with nimodipine in 19 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (15.79) | 18.2507 |
2000's | 6 (31.58) | 29.6817 |
2010's | 10 (52.63) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gibaldi, M | 1 |
Gandhi, VC; Jones, DJ; Stauderman, KA | 1 |
Azmitia, EC; Gu, XF | 1 |
Chen, B; Han, R; Li, JX; Liang, JH; Lu, Y; Wang, XH; Ye, XF; Zhang, P | 1 |
Choi, JS; Hahn, SJ; Hong, SH; Jo, YH; Kim, HJ; Kim, MJ; Kim, MS; Lee, YM; Min, DS; Rhie, DJ; Shim, EY; Yoon, SH | 1 |
Allegri, RF; Bagnatti, P; Taragano, FE | 1 |
Guo, XL; Hu, HX; Wang, Z; Xiao, W; Zhang, XB | 1 |
2 review(s) available for fluoxetine and nimodipine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions: Part I.
Topics: Antidepressive Agents, Tricyclic; Caffeine; Cimetidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Fluconazole; Fluoxetine; Hexobarbital; Humans; Ketoconazole; Nimodipine; Oxidoreductases; Pharmaceutical Preparations; Rifampin; Stereoisomerism; Warfarin; Zidovudine | 1992 |
2 trial(s) available for fluoxetine and nimodipine
Article | Year |
---|---|
A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression".
Topics: Aged; Antidepressive Agents, Second-Generation; Argentina; Calcium Channel Blockers; Cerebrovascular Disorders; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nimodipine; Outcome Assessment, Health Care; Secondary Prevention | 2005 |
[Acupuncture and drug for subcortical ischemic vascular disease complicated with depression: a randomized controlled trial].
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Aged; Cerebral Infarction; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Nimodipine; Treatment Outcome | 2014 |
15 other study(ies) available for fluoxetine and nimodipine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Fluoxetine-induced inhibition of synaptosomal [3H]5-HT release: possible Ca(2+)-channel inhibition.
Topics: Animals; Calcium; Calcium Channel Blockers; Cerebral Cortex; Fluoxetine; Male; Nimodipine; Potassium; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Spinal Cord; Synaptosomes | 1992 |
Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Stem; Carrier Proteins; Cells, Cultured; Clorgyline; Female; Fluoxetine; Membrane Glycoproteins; Membrane Transport Proteins; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Neurons; Nimodipine; p-Chloroamphetamine; Pregnancy; Rats; Rats, Sprague-Dawley; Reserpine; Selegiline; Serotonin; Serotonin Plasma Membrane Transport Proteins | 1993 |
L-type calcium channel blockers enhance 5-HTP-induced antinociception in mice.
Topics: 5-Hydroxytryptophan; Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Chloride; Chelating Agents; Drug Synergism; Egtazic Acid; Female; Fluoxetine; Injections, Intraventricular; Mice; Motor Activity; Nifedipine; Nimodipine; Pain Measurement; Pargyline; Selective Serotonin Reuptake Inhibitors; Verapamil | 2004 |
Fluoxetine inhibits ATP-induced [Ca(2+)](i) increase in PC12 cells by inhibiting both extracellular Ca(2+) influx and Ca(2+) release from intracellular stores.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channel Blockers; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Fluoxetine; Inositol; Membrane Potentials; Neural Inhibition; Nimodipine; Patch-Clamp Techniques; PC12 Cells; Rats; Selective Serotonin Reuptake Inhibitors; Thapsigargin; Time Factors; Tritium | 2005 |